Next Article in Journal
Integrated Bioinformatic Analyses and Immune Characterization of New Neisseria gonorrhoeae Vaccine Antigens Expressed during Natural Mucosal Infection
Next Article in Special Issue
MVA-Vectored Pentameric Complex (PC) and gB Vaccines Improve Pregnancy Outcome after Guinea Pig CMV Challenge, but Only gB Vaccine Reduces Vertical Transmission
Previous Article in Journal
Next-Generation Whole-Cell Pneumococcal Vaccine
Previous Article in Special Issue
Neutralizing Monoclonal Antibodies Reduce Human Cytomegalovirus Infection and Spread in Developing Placentas
Open AccessReview

Vaccine Vectors Harnessing the Power of Cytomegaloviruses

1
Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, 38124 Braunschweig, Germany
2
German Centre for Infection Research (DZIF), partner site Hannover/Braunschweig, 38124 Braunschweig, Germany
3
Centre for Individualised Infection Medicine (CiiM), a joint venture of Helmholtz Centre for Infection Research and Hannover Medical School, 30625 Hannover, Germany
*
Author to whom correspondence should be addressed.
Current address: Department of Dermatology, University of Zurich Hospital, University of Zurich, 8091 Zurich, Switzerland.
Vaccines 2019, 7(4), 152; https://doi.org/10.3390/vaccines7040152
Received: 20 July 2019 / Revised: 11 October 2019 / Accepted: 14 October 2019 / Published: 17 October 2019
(This article belongs to the Special Issue Cytomegalovirus Infection and Vaccine Development)
Cytomegalovirus (CMV) species have been gaining attention as experimental vaccine vectors inducing cellular immune responses of unparalleled strength and protection. This review outline the strengths and the restrictions of CMV-based vectors, in light of the known aspects of CMV infection, pathogenicity and immunity. We discuss aspects to be considered when optimizing CMV based vaccines, including the innate immune response, the adaptive humoral immunity and the T-cell responses. We also discuss the antigenic epitopes presented by unconventional major histocompatibility complex (MHC) molecules in some CMV delivery systems and considerations about routes for delivery for the induction of systemic or mucosal immune responses. With the first clinical trials initiating, CMV-based vaccine vectors are entering a mature phase of development. This impetus needs to be maintained by scientific advances that feed the progress of this technological platform. View Full-Text
Keywords: cytomegalovirus; vaccine vector; memory inflation; immunotherapy; immunization; vaccine development cytomegalovirus; vaccine vector; memory inflation; immunotherapy; immunization; vaccine development
Show Figures

Figure 1

MDPI and ACS Style

Ynga-Durand, M.A.; Dekhtiarenko, I.; Cicin-Sain, L. Vaccine Vectors Harnessing the Power of Cytomegaloviruses. Vaccines 2019, 7, 152.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop